Intellia Therapeutics Stock (NASDAQ: NTLA)

Intellia Therapeutics

INTELLIA THERAPEUTICS INC

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Bonn,,Germany,January,03,2024:,Facade,Of,The,Bonn,Marriott

News

Markets

Analyst Ratings

Trading Ideas

MDCX

NEXN

NTLA

OCGN

TEVA

WULF

XRAY

Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday

Ark Invest

Equities

Tech

ETFs

ARKK

ARKQ

BIDU

PATH

VCYT

ARK Invest made significant trades in NTLA, META, VCYT, SYM, BIDU, and PATH. These moves come amidst changes in stock prices. Read more for full details.

Cathie Wood&#39;s Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms

Display,Of,Stock,Market,Quotes

Intraday Update

Movers

BEAM

CLSK

ERAS

MVST

PCRX

QURE

RCKT

REPL

VERV

Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics Inc

Small Cap

Press Releases

NTLA Investors are Reminded of the Final Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - NTLA

Legal

Intellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – NTLA

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Earnings

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

Akebia Therapeutics

Ardelyx

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicara Therapeutics

CareDx

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Dyne Therapeutics

89bio

Geron

Gyre Therapeutics

Immunome

MiMedx Group

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Nurix Therapeutics

Novavax

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Arcus Biosciences

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Spyre Therapeutics

Vir Biotechnology

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Zymeworks

Guggenheim

Citigroup

Chardan Capital

Wolfe Research

HC Wainwright & Co.

Comments

Intellia Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell